The Johnson & Johnson COVID-19 vaccine is available once again after it was paused due to blood clot concerns. Meanwhile, the Centers for Disease Control and Prevention says millions of Americans may have missed their second doses of the Pfizer or Moderna vaccines.
A U.S. health panel says it’s time to resume use of Johnson & Johnson’s COVID-19 vaccine, despite a very rare risk of blood clots. Out of nearly 8 million people vaccinated before the U.S. suspended J&J’s shot, health officials uncovered 15 cases of a highly unusual kind of blood clot, three of them fatal.
U.S. authorities are weighing whether to resume the Johnson & Johnson vaccine more than a week after a pause was issued out of an abundance of caution. A government advisory panel is discussing a possible link between J&J’s shot and a handful of vaccine recipients who developed highly unusual blood clots. New guidance is expected later in the day.
A CDC advisory panel is expected to meet Friday to discuss recommendations on bringing back the Johnson & Johnson vaccine.
After an emergency meeting late Thursday, a Centers for Disease Control and Prevention Advisory Board has decided against recommending a restart of the Johnson & Johnson vaccine. The experts on the board say they need more information about the rare blood clots that have been reported.
On Tuesday, Prisma Health announced that they are pausing their use of the Johnson & Johnson coronavirus vaccine.
The South Carolina Department of Health and Environmental Control says they are putting an immediate pause on the distribution of the Johnson & Johnson coronavirus vaccine in the state.
According to Johns Hopkins University, the United States has now surpassed more than 560,000 deaths from COVID-19. As vaccinations ramp up, Johnson & Johnson is warning about a drop in the supply of its vaccine next week.
Good news for your kids who want to get vaccinated as well, Johnson & Johnson says it is testing its single-dose COVID-19 vaccine in teens. The company will start by adding 16 and 17-year-olds to its phase 2a trials, which have been ongoing since September.
The manufacturers of all three COVID-19 vaccines being used in the United States say they continue to conduct tests and are working to increase production capabilities.
